Podcast What's behind PharmaMar's journey on the stock market?
PharmaMar
rides one more day on the Ibex 35 due to the results of its investigations against the coronavirus.
The latest findings recognized by the journal
Science
on the chemical compound
plitidepsin
are the reason that this Tuesday its shares rise more than 20% on the Madrid stock market and are above 108 euros.
The prestigious scientific publication has endorsed the "powerful" activity of this compound against Covid-19 in an article that states that the Spanish laboratory test showed a 99% decrease in the
viral loads of SARS-CoV-2 in the lungs
of the animals under study.
The magazine also emphasizes that the toxicity that this product would have in human cells is "significantly lower" than that seen in other experiments.
The results are a further boost to the listing of a company that, since the beginning of the pandemic, has been among the favorites of investors.
Its titles ended 2020 with a 50% revaluation, although there were times of the year when it exceeded 100% and touched 150 euros.
The arrival of vaccines made them lose steam, but 2021 and the new results have put the company back in the target of the markets.
Only in this month of January has it managed to match that 50% accumulated increase and its
capitalization reaches 1,980 million euros.
"The studies of PharmaMar and other companies such as the American
Gilead
were destined to cure the disease once it was infected, so the emergence of vaccines that would prevent precisely this situation significantly penalized their price. However, in the middle of the third wave, c
With the hospitals once again saturated
, and in view of the numerous obstacles that the different administrations are encountering to be able to vaccinate the population, this news has given new impetus to its price and has led it to exceed important levels in the graph ", explains
Aitor Méndez, an
analyst at IG Markets
.
At the head of the Ibex
The laboratory led the increases this Tuesday in the Ibex 35, ahead even of
Naturgy
, which advanced by around 15% due to the impulse of the offer of the IFM fund to acquire 22% of the company.
Banco
Sabadell, Merlin Properties and Meliá
are the other protagonists of the session, with increases of more than 3% that allow the selective gain more than 1% and touch 8,000 points again.
At the opposite extreme,
Solaria
(-7%),
Siemens Gamesa and Cellnex
are the worst values of the day and prevent the Spanish index from approaching the increases of other European markets such as the Dax in Frankfurt (+1.9 %).
The Cac 40 in Paris (+ 1.4%), the Ftse Mib in Milan (+ 1.2%) and the Ftse 100 in London (+ 0.3%) also remain green despite the slowdown in the campaigns vaccination and the general increase in infections in Europe.
According to the criteria of The Trust Project
Know more
economy
Business
Coronavirus
Covid 19
Catalan doctors and Quim Torra criticize that the Generalitat does not increase restrictions against the coronavirus
The Generalitat will terminate the contract with Ferrovial to track the coronavirus in Catalonia
Coronavirus The Generalitat decrees the municipal confinement and new restrictions due to the negative data of the Covid in Catalonia
See links of interest
Holidays 2021
Spain - Hungary, live
Athletic Club - Getafe
FC Cartagena - Mirandés
Real Valladolid - Raise
Crystal Palace - West Ham United